Table 3.
G-CSF type in first cycle or across all cycles in patients receiving other physician choice options
| On-body injector | Other physician choice | |
|---|---|---|
| (n = 1624) | (n = 951) | |
| G-CSF utilization in cycle 1—n (%) | ||
| OBI | 1624 (100.0) | 0 (0.0) |
| Pegfilgrastim or biosimilar pegfilgrastim prefilled syringe | 0 (0.0) | 587 (61.7) |
| Short-acting G-CSF | 0 (0.0) | 70 (7.4) |
| No G-CSF | 0 (0.0) | 294 (30.9) |
| G-CSF utilization in all cyclesa—n (%) | ||
| OBI | 1624 (100.0) | 103 (10.8) |
| Pegfilgrastim or biosimilar pegfilgrastim prefilled syringe | 80 (4.9) | 610 (64.1) |
| Short-acting G-CSFb | 20 (1.2) | 98 (10.3) |
| No G-CSF | 80 (4.9) | 314 (33.0) |
G-CSF, granulocyte colony–stimulating factor; OBI, on-body injector
aCategories are not mutually exclusive
b121 patients were administered short-acting G-CSFs via a prefilled syringe, and 2 patients received short-acting G-CSFs from a vial, accounting for less than 0.1% of the study population (n = 2575)